1. Home
  2. HOPE vs IOVA Comparison

HOPE vs IOVA Comparison

Compare HOPE & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hope Bancorp Inc.

HOPE

Hope Bancorp Inc.

HOLD

Current Price

$14.00

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$8.77

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOPE
IOVA
Founded
1986
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2000
2008

Fundamental Metrics

Financial Performance
Metric
HOPE
IOVA
Price
$14.00
$8.77
Analyst Decision
Buy
Buy
Analyst Count
2
10
Target Price
$14.50
$9.00
AVG Volume (30 Days)
853.7K
18.3M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
4.53%
N/A
EPS Growth
N/A
14.84
EPS
0.49
N/A
Revenue
N/A
N/A
Revenue This Year
$42.00
$47.74
Revenue Next Year
$19.66
$40.31
P/E Ratio
$28.49
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.80
$1.76
52 Week High
$14.59
$9.36

Technical Indicators

Market Signals
Indicator
HOPE
IOVA
Relative Strength Index (RSI) 53.88 69.15
Support Level $13.82 $3.57
Resistance Level $14.54 $9.36
Average True Range (ATR) 0.23 0.58
MACD -0.04 -0.01
Stochastic Oscillator 52.94 76.48

Price Performance

Historical Comparison
HOPE
IOVA

About HOPE Hope Bancorp Inc.

Hope Bancorp Inc is a bank holding company engaged in providing financial services. It offers core business banking products for small and medium-sized businesses and individuals. Services offered by the bank include online banking, mobile banking, mortgage loans, credit cards, investment and wealth management services, and other banking services.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Share on Social Networks: